Dr. Scott Antonia, MD

• Oncology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Yale School Of Medicine

  Fellowship Hospital, 1994

• Yale New Haven Hospital

  Internship Hospital, 1990

• University Of Connecticut School Of Medicine

  Medical School, 1989

• The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts, 2016-03-02

• Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC, 2019-10-14

• A Bayesian pick-the-winner design in a randomized phase II clinical trial, 2017-07-07

• IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells, 2022-08-16

• Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer, 2018-05-03

• Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T cells, 2020-08-07

• Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer, 2018-05-14

• A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses, 2019-11-20

• Clinical associations of mucin 1 in human lung cancer and precancerous lesions, 2018-11-02

• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC), 2018-07-17

• Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage, 2021-07-26

• Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma, 2015-12-31

• Differential association ofSTK11andTP53withKRASmutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma, 2015-10-19

• Non-Small Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy, 2015-06-26

• Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer, 2015-09-27

• Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer, 2019-08-13

• Strategies for power calculations in predictive biomarker studies in survival data, 2016-09-19

• A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma, 2018-09-12

• Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, 2012-06-02

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect, 2011-07-21

• A phase I study of indoximod in patients with advanced malignancies, 2016-03-20

• Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma, 2020-11-17

• HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma, 2016-03-10

• Building a Long Distance Training Program to Enhance Clinical Cancer Research Capacity in Puerto Rico, 2015-03-18

• Randomized-controlled phase II trial of salvage chemotherapy after immunization with aTP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer, 2018-12-27

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts National Harbor, MD, USA. 9-13 November 2016, 2016-12-08

• Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer, 2018-04-12

• Progressive hypoventilation due to mixed CD8+and CD4+lymphocytic polymyositis following tremelimumab - durvalumab treatment, 2017-07-18

• Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance, 2019-03-18

• Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032, 2018-10-10